Skip to content

Serum Uromodulin – A Potential Biomarker to Predict Response to Lupus Nephritis Treatment in Adults

Serum Uromodulin – A Potential Biomarker to Predict Response to Lupus Nephritis Treatment in Adults

Status
Recruiting
Phases
Phase 3
Study type
Observational
Source
TCTR
Registry ID
TCTR20181002001
Enrollment
43
Registered
2018-10-02
Start date
2018-01-04
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active lupus nephritis Serum uromodulin Lupus nephritis Biomarker Remission

Interventions

Patients with active lupus nephritis as defined in the inclusion criteria who require induction therapy according to physician opinion
Diagnostic
Patients with active lupus nephritis requiring induction therapy

Sponsors

Renal Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age of 18 or older 2. Diagnosed systemic lupus erythematosus (SLE) according to 1997 American College of Rheumatology (ACR) criteria 3. Patients with active lupus nephritis requiring induction therapy according to physician opinion. However, kidney biopsy to confirm lupus nephritis is not required. Active lupus nephritis is defined as one of the following: 3.1 Presence of urine protein of more than 0.5 gram per day and presence of red blood cells (RBC) in urine of more than 5 cells per high power field or presence of RBC cast or 3.2 Presence of urine protein of more than 3.0 gram per day if RBC in the urine less than 5 cells per high power field and no RBC cast 3.3 If kidney biopsy was done, presence of the evidence of active lupus nephritis class III, IV or V according to the 2003 International Society for Nephrology/Renal Pathology Society (ISN/RPS) classification criteria

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Patients with antiphospholipid syndrome (APS) 3. Patients with thrombotic thrombocytopenic purpura (TTP) 4. Patients with overlapping syndrome 5. Patients who have estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73 m2.

Design outcomes

Primary

MeasureTime frame
Clinical response to induction therapy Six months after induction therapy Serum creatinine, urine protein, and urine analysis

Secondary

MeasureTime frame
N/A N/A N/A

Countries

Thailand

Contacts

Public ContactKajohnsak Noppakun

Chiang Mai University

kajohnsak.noppakun@cmu.ac.th+66815953465

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026